Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), is pleased to announce its involvement in a renewable green initiative involving its UK, Cramlington site.
• UK Green Investment Bank plc and John Laing Investments Ltd commit £50 million to 27.7 MW Cramlington Combined Heat and Power plant
• Finished facility will generate 223 GWh of renewable electricity annually
• Generated electricity will be split between Aesica, one other pharmaceutical company and the National Grid
• The reduction in greenhouse gas emissions will equate to the removal of 25,000 cars from the UK’s roads over  years
• Project will create 250 construction jobs, 25 positions in plant operations and approximately 20 jobs in the supply chain
UK Green Investment Bank plc (GIB) and John Laing Investments Limited (JLI) have committed £50 million of equity to a new £137 million renewable energy facility in North East England, developed by Estover Energy. The biomass Combined Heat and Power (CHP) plant in Cramlington, Northumberland, will generate 223 GWh of renewable electricity annually. It is expected to reduce greenhouse gas emissions by circa  kt CO2e annually, the equivalent of taking 25,000 cars off the road during its lifetime.
Aesica Pharmaceuticals, together with another pharma company, will benefit directly from its output, alongside the National Grid. Green electricity will be routed to Aesica’s Cramlington site located in an adjacent industrial estate. The energy plant will also have the potential to provide 5 MW of renewable heat to neighbouring facilities.
GIB will make a £23 million investment in the project, with JLI investing in a stake worth £27 million. Barclays will provide the remainder of the funding as debt, 60% of which will be guaranteed by the Danish export credit agency Eksport Kredit Fonden (EKF).
The construction of the plant will be undertaken by a joint venture between Burmeister & Wain Energy A/S (BWE) and Burmeister & Wain Scandinavian Contractors A/S (BWSC). BWSC will operate the plant upon completion. Up to 250 jobs are expected to be created during the construction process, while 25 permanent positions will be maintained at the operational facility.
Fuel for the plant will be provided by Stobart Biomass Products Limited, plus local growers and forest industry suppliers.
Ian Muir, Managing Director at Aesica commented: “Our company is committed to best environmental practice and indeed our Cramlington site complies in full with ISO 14001and all appropriate environmental legislation. Consequently, we are always on the look-out for maximising the use of green, environmentally friendly energy.”
He continued: “We are therefore delighted to receive our energy supply moving forwards from the biomass combined heat and power plant and to playing our role through this initiative in reducing greenhouse emissions.”
Ed Northam, Head of Investment Banking at the UK Green Investment Bank, said:
“The Cramlington plant promises to create local jobs, support an industry whose vitality is essential to the growth of the regional economy and help cut UK greenhouse gas emissions while promoting the country’s adoption of green energy sources.”
• Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.
About Consort Medical:
• Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities
• Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740/6745 or e-mail; email@example.com